Phospho-TAU Antibodies for Plasma pTau-217 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Alzheimer's disease and other tauopathies lack sensitivity and specificity in detecting phosphorylated tau residues, particularly pTau-217, which are critical for early-stage diagnosis and prognosis, and there is a need for improved biomarkers in plasma and serum samples to track disease progression.
Innovation Solution
Development of antibodies with specific variable domains that can detect phosphorylated tau isoforms such as pTau-181, pTau-217, pTau-212, pTau-231, and pTau-214 in plasma and serum samples, using immunoassays with high specificity and sensitivity, allowing for accurate detection and prognosis of Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then general tau detection is possible, but sensitivity and specificity for detecting phosphorylated tau residues (particularly pTau-217) are insufficient
Solution Approach 1:
The patent develops antibodies with highly specific binding properties targeting particular phosphorylated tau residues (pTau-181, pTau-217, pTau-212, pTau-231, pTau-214) rather than general tau detection. Each antibody is engineered to recognize specific epitopes on phosphorylated tau, providing localized and precise detection capability for specific disease-relevant residues.
Solution Approach 2:
The invention changes the binding parameters of antibodies to achieve picogram-per-milliliter detection limits. By optimizing antibody affinity and specificity parameters, the assay achieves unprecedented sensitivity (limit of detection as low as 1.0 pg/mL) for phosphorylated tau residues in plasma and serum samples.
2Measurement precision
If CSF samples are used for biomarker detection, then high sensitivity is achieved, but invasiveness and patient compliance become issues
Solution Approach 1:
The patent uses plasma and serum as intermediary matrices that can be non-invasively collected and still provide reliable detection of phosphorylated tau biomarkers. These blood-based intermediaries serve as surrogates for CSF, maintaining diagnostic sensitivity while eliminating the need for lumbar puncture procedures.
3Reliability
If early-stage diagnosis is pursued, then prognosis accuracy improves, but current methods lack sufficient sensitivity for preclinical detection
Solution Approach 1:
The patent enables preliminary detection of phosphorylated tau biomarkers in the preclinical and prodromal stages of Alzheimer's disease, before clinical symptoms manifest. By detecting pTau residues at extremely low concentrations (1.0 pg/mL), the assay allows for early intervention and prognosis assessment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies provide high specificity and sensitivity in detecting phosphorylated tau residues, enabling early-stage diagnosis and prognosis of Alzheimer's disease, with a limit of detection as low as 1.0 picogram per milliliter, and can be used in conjunction with other biomarkers for comprehensive disease analysis.
Implementation Method 1
Development of antibodies with specific variable domains that can detect phosphorylated tau isoforms such as pTau-181, pTau-217, pTau-212, pTau-231, and pTau-214 in plasma and serum samples, using immunoassays with high specificity and sensitivity
Data Source
AI summary
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.